# US 2024/0302365 A1 · Method for diagnosing chronic urticaria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0302365 A1
- Document ID: US20240302365A1
- Status: Published application
- Kind: A1
- Application number: 18/255,680
- Filed: 2021-11-12
- Published: 2024-09-12
- Earliest claimed: 2020-12-04
- Assignees: Md Healthcare Inc.; Ajou University Industry-Academic Cooperation Foundation
- Applicants: Md Healthcare Inc.; Ajou University Industry-Academic Cooperation Foundation
- Inventors: Hae-Sim PARK; Youngwoo CHOI; Yoon-Keun KIM
- Web page: https://patentgrep.com/patent/US20240302365A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6854: {Immunoglobulins}
- G01N 2333/212: Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella or Psychrobacter
- G01N 2800/24: Immunology or allergic disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a method for providing information on chronic urticaria and, more specifically, the provided is a method for diagnosing chronic urticaria by measuring an allergen-specific IgE antibody for a vesicle derived from Acinetobacter bacteria; a diagnostic composition using the same; and the like.

## Claims

### Claim 1

A method for diagnosing chronic urticaria, comprising:
(a) measuring a level of an allergen-specific IgE antibody against Acinetobacter baumannii-derived vesicles in a biological sample; and
(b) classifying a case in which the level of the measured allergen-specific IgE antibody increases compared to those in normal persons as the chronic urticaria.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is any one or more selected from the group consisting of blood, plasma, serum, bone marrow, saliva, urine, and feces.

### Claim 3 (depends on 1)

The method of claim 1, wherein the measuring of the level of the allergen-specific IgE antibody comprises any one or more selected from the group consisting of Western blot, an enzyme-linked immunosorbent assay (ELISA), ImmunoCAP, a radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistostaining, an immunoprecipitation assay, a complement fixation assay, flow cytometry (a fluorescence activated cell sorter (FACS)), and protein chips.

### Claim 4 (depends on 1)

The method of claim 1, wherein a steroid preparation is administered or applied as a therapeutic agent to the subject classified as the chronic urticaria.

### Claim 5

A composition for diagnosing chronic urticaria comprising a substance for measuring a level of an allergen-specific IgE antibody against Acinetobacter baumannii-derived vesicles.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the substance is an antigen, an antibody, a peptide, or an aptamer, which specifically binds to the allergen-specific IgE antibody against the Acinetobacter baumannii-derived vesicles.

### Claim 7

A kit for diagnosing chronic urticaria comprising a substance for measuring a level of an allergen-specific IgE antibody against Acinetobacter baumannii-derived vesicles.

### Claim 8 (depends on 7)

The kit of claim 7, wherein the substance is an antigen, an antibody, a peptide, or an aptamer, which specifically binds to the allergen-specific IgE antibody against the Acinetobacter baumannii-derived vesicles.

### Claim 9

(canceled)
